Patel P, Alghareeb R, Hussain A, Maheshwari M, Khalid N
Cureus. 2022; 14(6):e26314.
PMID: 35911302
PMC: 9314235.
DOI: 10.7759/cureus.26314.
Asmarani Y, Supriatno , Haniastuti T
Int J Dent. 2022; 2022:9579326.
PMID: 35847347
PMC: 9279093.
DOI: 10.1155/2022/9579326.
Ghazzaui N, Issaoui H, Ferrad M, Carrion C, Cook-Moreau J, Denizot Y
Blood Adv. 2020; 4(1):28-39.
PMID: 31899800
PMC: 6960469.
DOI: 10.1182/bloodadvances.2019000845.
Hickmann A, Frick M, Hadaschik D, Battke F, Bittl M, Ganslandt O
BMC Cancer. 2019; 19(1):192.
PMID: 30823914
PMC: 6397454.
DOI: 10.1186/s12885-019-5394-x.
Dojcinov S, Fend F, Quintanilla-Martinez L
Pathogens. 2018; 7(1).
PMID: 29518976
PMC: 5874754.
DOI: 10.3390/pathogens7010028.
Epstein-Barr virus-associated lymphomas.
Shannon-Lowe C, Rickinson A, Bell A
Philos Trans R Soc Lond B Biol Sci. 2017; 372(1732).
PMID: 28893938
PMC: 5597738.
DOI: 10.1098/rstb.2016.0271.
The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.
Ghazzaui N, Saintamand A, Issaoui H, Vincent-Fabert C, Denizot Y
Oncotarget. 2016; 8(4):7059-7067.
PMID: 27729620
PMC: 5351691.
DOI: 10.18632/oncotarget.12535.
Epstein-Barr virus and Burkitt lymphoma.
Rowe M, Fitzsimmons L, Bell A
Chin J Cancer. 2014; 33(12):609-19.
PMID: 25418195
PMC: 4308657.
DOI: 10.5732/cjc.014.10190.
Cumulative Epigenetic Abnormalities in Host Genes with Viral and Microbial Infection during Initiation and Progression of Malignant Lymphoma/Leukemia.
Oka T, Sato H, Ouchida M, Utsunomiya A, Yoshino T
Cancers (Basel). 2013; 3(1):568-81.
PMID: 24212629
PMC: 3756377.
DOI: 10.3390/cancers3010568.
Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus.
Westhoff Smith D, Sugden B
Viruses. 2013; 5(1):226-40.
PMID: 23325328
PMC: 3564119.
DOI: 10.3390/v5010226.
Denis Burkitt and the African lymphoma.
Magrath I
Ecancermedicalscience. 2012; 3:159.
PMID: 22276020
PMC: 3224008.
DOI: 10.3332/ecancer.2009.159.
Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression.
Yee J, White R, Anderton E, Allday M
PLoS One. 2011; 6(12):e28506.
PMID: 22174825
PMC: 3235132.
DOI: 10.1371/journal.pone.0028506.
Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
Pujals A, Renouf B, Robert A, Chelouah S, Hollville E, Wiels J
Cell Death Dis. 2011; 2:e184.
PMID: 21796156
PMC: 3199720.
DOI: 10.1038/cddis.2011.67.
Novel therapeutics for aggressive non-Hodgkin's lymphoma.
Mahadevan D, Fisher R
J Clin Oncol. 2011; 29(14):1876-84.
PMID: 21483007
PMC: 3138544.
DOI: 10.1200/JCO.2010.32.7171.
Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.
Sotillo E, Laver T, Mellert H, Schelter J, Cleary M, McMahon S
Oncogene. 2011; 30(22):2587-94.
PMID: 21297663
PMC: 3128883.
DOI: 10.1038/onc.2010.634.
DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma.
Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M
Br J Cancer. 2010; 103(2):265-74.
PMID: 20551953
PMC: 2906728.
DOI: 10.1038/sj.bjc.6605711.
Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP.
Skalska L, White R, Franz M, Ruhmann M, Allday M
PLoS Pathog. 2010; 6(6):e1000951.
PMID: 20548956
PMC: 2883600.
DOI: 10.1371/journal.ppat.1000951.
How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?.
Allday M
Semin Cancer Biol. 2009; 19(6):366-76.
PMID: 19635566
PMC: 3770905.
DOI: 10.1016/j.semcancer.2009.07.007.
Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.
Rowe M, Kelly G, Bell A, Rickinson A
Semin Cancer Biol. 2009; 19(6):377-88.
PMID: 19619657
PMC: 3764430.
DOI: 10.1016/j.semcancer.2009.07.004.
c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N, Durand-Panteix S, Schlee M, Gromminger S, Schuhmacher M, Holzel M
J Virol. 2009; 83(10):5014-27.
PMID: 19264782
PMC: 2682111.
DOI: 10.1128/JVI.02264-08.